Atazolisumab cancer treatment injection??

Reading File

Finding Sources

Searching PubMed

atezolizumab cancer immunotherapy

Searching the Web

atezolizumab Tecentriq cancer treatment 2025 indications mechanism

Reading File

Here is a thorough overview of Atezolizumab (Tecentriq) - I believe that's the drug you are asking about (there is no drug called "Atazolisumab"):

Atezolizumab (Tecentriq)

What it is

Atezolizumab (brand name Tecentriq) is a humanized IgG1 monoclonal antibody that targets PD-L1 (Programmed Death-Ligand 1). It belongs to the class of drugs called immune checkpoint inhibitors. It was first FDA-approved in 2016.

Goodman & Gilman's Pharmacological Basis of Therapeutics

Mechanism of Action

Cancer cells "hide" from the immune system by expressing PD-L1 on their surface. PD-L1 binds to the PD-1 receptor on T-cells, sending a "don't attack me" signal that shuts down T-cell activity.

Atezolizumab blocks PD-L1, preventing it from binding to PD-1. This releases the brakes on T-cells, allowing them to recognize and destroy cancer cells.

PD-L1 blockade mechanism showing active T cell killing tumor

Active T-cell restored to kill tumor cells once PD-L1 is blocked - Fishman's Pulmonary Diseases

How it is Given

Intravenous (IV) infusion - administered over 60 minutes, every 3 weeks
There is also a newer formulation: Tecentriq Hybreza (atezolizumab + hyaluronidase-tqjs) which can be given subcutaneously (under the skin)
Half-life: approximately 27 days
Goodman & Gilman's, p.1443

Approved Cancer Indications

Cancer Type	Setting	Notes
Non-small cell lung cancer (NSCLC)	1st line, 2nd line, adjuvant	Requires PD-L1 testing for some indications; no EGFR/ALK mutations
Extensive-stage small cell lung cancer (ES-SCLC)	1st line + carboplatin/etoposide	First regimen in 30 years to improve SCLC survival
Urothelial carcinoma (bladder cancer)	Metastatic	PD-L1 expression required for some settings
Triple-negative breast cancer (TNBC)	1st line + paclitaxel
Hepatocellular carcinoma (HCC)	1st line + bevacizumab	Unresectable or metastatic
Melanoma	BRAF V600 mutation-positive	With cobimetinib + vemurafenib
Cervical cancer adenocarcinoma	Selected settings	Added 2025

Goodman & Gilman's; Genentech prescribing information (2025)

Key Side Effects

Common (≥20% of patients):

Fatigue
Decreased appetite
Shortness of breath (dyspnea)
Cough
Nausea
Musculoskeletal pain
Constipation

Immune-related adverse effects (irAEs) - because it activates the immune system, it can cause autoimmune-like reactions:

Hepatitis (liver inflammation)
Colitis (gut inflammation)
Thyroid disorders (hypothyroidism/hyperthyroidism)
Adrenal insufficiency
Hypophysitis (pituitary inflammation)
Rare but serious: type 1 diabetes, pancreatitis, myasthenia gravis, Guillain-Barre syndrome, eye inflammation

Important: Patients with myasthenia gravis should avoid or use this drug with extreme caution as it can trigger severe flares.

Pregnancy: Can cause embryo-fetal harm - women of childbearing potential must be warned.

Goodman & Gilman's, p.1443; Bradley & Daroff's Neurology

Recent Evidence (2024-2025)

Recent systematic reviews confirm atezolizumab's efficacy in:

NSCLC (squamous and non-squamous): Network meta-analysis supports its role in advanced squamous NSCLC (PMID 41035637)
HCC: Atezolizumab + bevacizumab remains a top regimen for unresectable HCC based on quality of life and survival data (PMID 40810932)
Triple-negative breast cancer: Confirmed role in metastatic TNBC (PMID 39742383)

Important Notes

PD-L1 testing is required before using atezolizumab for certain indications - not all patients qualify.
It is not used in cancers with EGFR mutations or ALK rearrangements in NSCLC (targeted therapy is preferred there).
Immune-related side effects can appear weeks to months after starting treatment and may require steroids or stopping the drug.

Disclaimer: This information is for educational purposes only. Atezolizumab must be prescribed and monitored by a qualified oncologist. Dosing, eligibility, and management of side effects require specialist oversight.

Is it used in adenocarcinoma of stomach

Finding Sources

Searching PubMed

atezolizumab gastric adenocarcinoma

Searching the Web

atezolizumab gastric stomach adenocarcinoma FDA approval 2025

Reading Article

Finding Sources

Here is a clear, evidence-based answer:

Atezolizumab in Gastric Adenocarcinoma

Short Answer: Not FDA-approved for gastric cancer, but actively studied in clinical trials

As of May 2026, atezolizumab does not have an FDA-approved indication specifically for gastric or gastroesophageal junction (GEJ) adenocarcinoma. The checkpoint inhibitors with approved roles in gastric cancer are nivolumab and pembrolizumab (both PD-1 inhibitors, not PD-L1 like atezolizumab).

What IS Approved for Gastric Adenocarcinoma (2025)

Drug	Target	Indication
Nivolumab (Opdivo)	PD-1	1st-line metastatic gastric/GEJ + chemo; adjuvant post-surgery
Pembrolizumab (Keytruda)	PD-1	HER2+, PD-L1 CPS ≥1 gastric/GEJ + trastuzumab + chemo (full FDA approval March 2025)
Durvalumab (Imfinzi)	PD-L1	Resectable gastric/GEJ - neoadjuvant + adjuvant setting (FDA approved late 2025)

Notably, durvalumab - another PD-L1 inhibitor like atezolizumab - received its first gastric cancer approval in late 2025, but atezolizumab has not followed suit yet.

Atezolizumab in Gastric Cancer - Clinical Trial Evidence

There are two key trials showing promising (though early) results:

1. DANTE Trial (Phase II/III) - Resectable Esophagogastric Adenocarcinoma

Regimen: Atezolizumab + FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) perioperatively
Key findings: Adding atezolizumab improved tumor downstaging and pathologic complete response rates (24% vs 15%, p=0.032) compared to FLOT alone
Best results in: PD-L1 CPS ≥10 (33% vs 12% pCR) and MSI-high tumors (63% vs 27% pCR)
Safety: Comparable to FLOT alone
J Clin Oncol, 2024 (PMID 37963317)

2. Phase II RCT - HER2-positive Gastric/GEJ Cancer (JAMA Oncology, 2025)

Regimen: Atezolizumab + trastuzumab + XELOX (capecitabine + oxaliplatin) vs trastuzumab + XELOX alone
Key finding: pCR rate significantly higher with atezolizumab added (38% vs 14%)
Population: Locally advanced, resectable, ERBB2 (HER2)-positive gastric/GEJ cancer
JAMA Oncol, 2025 (PMID 40244574)

3. PANDA Trial (Phase II) - Neoadjuvant Setting

Tested atezolizumab + chemotherapy as neoadjuvant therapy in gastric and GEJ adenocarcinoma
Published in Nature Medicine, 2024 (PMID 38191613)

Key Biomarkers That Matter

The trials suggest atezolizumab is most likely to benefit patients who are:

MSI-high (microsatellite instability-high) - strongest response
PD-L1 CPS ≥10 - better pathologic responses
HER2-positive - when combined with trastuzumab

Bottom Line

Status	Details
FDA-approved for gastric cancer?	No
Being studied in gastric cancer?	Yes - active Phase II/III trials
Promising signals?	Yes, especially in MSI-H and PD-L1-high tumors
Standard of care?	No - nivolumab and pembrolizumab are preferred

So while atezolizumab is not the current standard for gastric adenocarcinoma, it is under active investigation and may gain approval in the future, particularly in the perioperative or HER2-positive settings if Phase III data matures favorably.

This is a shared conversation. Sign in to Orris to start your own chat.